Qlaira® - innovative estradiol-based oral contraceptive available in Europe
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany, is starting the European roll-out of its new oral contraceptive Qlaira® (estradiol valerate/dienogest). From May 15, 2009, Qlaira® will be available in several European countries, including Germany. More European countries will follow from autumn 2009 onwards.
Boehringer Ingelheim and DeveloGen AG announce agreement
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and DeveloGen AG, have announced the signing of an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders.
Roche provides additional donation of 5.65 million packs of Tamiflu to WHO
- Details
- Category: Roche
Roche has announced a new donation to the World Health Organization (WHO) of 5.65 million courses of treatment of the antiviral drug Tamiflu (oseltamivir). This donation includes:
- Replenishment of the Regional Stockpile of 2 million treatment courses of Tamiflu to be held by the WHO and used to address regional outbreaks,
Sanofi-aventis builds a New Vaccine Manufacturing Facility in France
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), the world's leading vaccine manufacturer, officially launched the construction of a new Sanofi Pasteur vaccine manufacturing center in Neuville-sur-Saône, France, in a ceremony attended by Gérard Collomb, Senator and Mayor of Lyon, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, Dr. Elias A. Zerhouni, Science and Technology Adviser for sanofi-aventis.
AstraZeneca Announces Top Line Results From Pivotal Phase III Study for BRILINTA
- Details
- Category: AstraZeneca
AstraZeneca has announced top line results from the phase III trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that BRILINTA (ticagrelor), the investigational oral antiplatelet treatment for acute coronary syndromes (ACS), has achieved a statistically significant primary efficacy endpoint versus clopidogrel, in the prevention of cardiovascular (CV) events in patients with ACS.
Novo Nordisk reaches settlements regarding Oil-for-Food activities
- Details
- Category: Novo Nordisk
Novo Nordisk announced today that it has entered into a consent agreement with the US Securities and Exchange Commission (SEC) and a deferred prosecution agreement with the US Department of Justice (DOJ) resolving their investigations of the company's sales to Iraq during 2000 to 2003 under the UN's Oil-for-Food programme.
Nycomed files European marketing authorisation application for Daxas®
- Details
- Category: Nycomed
Nycomed has announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Daxas® as a once-daily oral treatment for patients with COPD associated with chronic bronchitis. The MAA submission is based on encouraging results from four Phase III trials of Daxas (roflumilast) in the treatment of symptomatic COPD.
More Pharma News ...
- GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
- Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch
- Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement
- GlaxoSmithKline update: influenza A (H1N1)
- Outcome of new Mirapexin®/Sifrol® (pramipexole) study
- Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors
- Pfizer Reports First-Quarter 2009 Results